Grandfield & Dodd LLC held its position in shares of Celgene Corporation (NASDAQ:CELG) during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 2,630 shares of the biopharmaceutical company’s stock at the close of the second quarter. Grandfield & Dodd LLC’s holdings in Celgene Corporation were worth $342,000 as of its most recent filing with the SEC.

Other large investors have also bought and sold shares of the company. Neuberger Berman Group LLC increased its holdings in Celgene Corporation by 4.0% during the 1st quarter. Neuberger Berman Group LLC now owns 1,844,837 shares of the biopharmaceutical company’s stock valued at $229,553,000 after acquiring an additional 71,729 shares in the last quarter. Lincoln Capital Corp increased its holdings in Celgene Corporation by 0.6% during the 2nd quarter. Lincoln Capital Corp now owns 30,580 shares of the biopharmaceutical company’s stock valued at $3,971,000 after acquiring an additional 185 shares in the last quarter. Swiss National Bank increased its holdings in Celgene Corporation by 27.2% during the 1st quarter. Swiss National Bank now owns 2,746,896 shares of the biopharmaceutical company’s stock valued at $341,796,000 after acquiring an additional 588,000 shares in the last quarter. Russell Investments Group Ltd. increased its holdings in Celgene Corporation by 9.2% during the 2nd quarter. Russell Investments Group Ltd. now owns 641,697 shares of the biopharmaceutical company’s stock valued at $83,344,000 after acquiring an additional 54,210 shares in the last quarter. Finally, Boston Partners increased its holdings in Celgene Corporation by 0.3% during the 1st quarter. Boston Partners now owns 197,861 shares of the biopharmaceutical company’s stock valued at $24,620,000 after acquiring an additional 541 shares in the last quarter. Hedge funds and other institutional investors own 79.33% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by Daily Political and is the property of of Daily Political. If you are reading this piece of content on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://www.dailypolitical.com/2017/09/26/celgene-corporation-celg-position-held-by-grandfield-dodd-llc.html.

In other Celgene Corporation news, Director Gilla Kaplan sold 7,500 shares of the company’s stock in a transaction that occurred on Wednesday, August 2nd. The stock was sold at an average price of $134.52, for a total transaction of $1,008,900.00. Following the completion of the sale, the director now owns 76,301 shares of the company’s stock, valued at $10,264,010.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Michael D. Casey sold 9,250 shares of the company’s stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $139.03, for a total value of $1,286,027.50. Following the sale, the director now directly owns 9,250 shares of the company’s stock, valued at approximately $1,286,027.50. The disclosure for this sale can be found here. Insiders have sold 44,506 shares of company stock valued at $6,019,761 in the last ninety days. Company insiders own 0.95% of the company’s stock.

Celgene Corporation (NASDAQ:CELG) opened at 144.94 on Tuesday. Celgene Corporation has a 52-week low of $96.93 and a 52-week high of $146.13. The stock’s 50 day moving average is $135.45 and its 200-day moving average is $127.81. The firm has a market capitalization of $113.39 billion, a PE ratio of 44.89 and a beta of 1.89.

Celgene Corporation (NASDAQ:CELG) last announced its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.61 by $0.21. The firm had revenue of $3.27 billion during the quarter, compared to analysts’ expectations of $3.23 billion. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The company’s revenue was up 18.7% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.44 earnings per share. Equities analysts expect that Celgene Corporation will post $7.32 earnings per share for the current year.

CELG has been the subject of several recent research reports. Cantor Fitzgerald set a $160.00 target price on shares of Celgene Corporation and gave the company a “buy” rating in a report on Thursday, July 6th. Oppenheimer Holdings, Inc. set a $148.00 price target on shares of Celgene Corporation and gave the stock a “buy” rating in a report on Thursday, June 8th. Cann reiterated a “buy” rating on shares of Celgene Corporation in a report on Wednesday, June 7th. Canaccord Genuity set a $156.00 price target on shares of Celgene Corporation and gave the stock a “buy” rating in a report on Tuesday, June 6th. Finally, Mizuho lifted their price target on shares of Celgene Corporation from $130.00 to $134.00 and gave the stock a “buy” rating in a report on Thursday, June 1st. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, twenty-one have issued a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $149.34.

Celgene Corporation Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.